BiomX Inc (PHGE)
0.4446
-0.03
(-7.18%)
USD |
NYAM |
May 01, 16:00
0.4545
+0.01
(+2.23%)
After-Hours: 18:37
BiomX Cash from Financing (TTM): 2.899M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 2.899M |
September 30, 2023 | 4.223M |
June 30, 2023 | 5.766M |
March 31, 2023 | 1.305M |
December 31, 2022 | 0.292M |
September 30, 2022 | 4.272M |
June 30, 2022 | 32.10M |
March 31, 2022 | 32.96M |
December 31, 2021 | 37.28M |
Date | Value |
---|---|
September 30, 2021 | 33.31M |
June 30, 2021 | 5.287M |
March 31, 2021 | 4.46M |
December 31, 2020 | 0.134M |
September 30, 2020 | -0.379M |
June 30, 2020 | -0.4381M |
March 31, 2020 | -0.4904M |
September 30, 2019 | 70.38M |
June 30, 2019 | 70.90M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.4904M
Minimum
Mar 2020
70.90M
Maximum
Jun 2019
16.90M
Average
4.366M
Median
Cash from Financing (TTM) Benchmarks
Taro Pharmaceutical Industries Ltd | 0.00 |
InspireMD Inc | 37.53M |
Alpha Tau Medical Ltd | -- |
Pluri Inc | -- |
Raphael Pharmaceutical Inc | 1.145M |